Vanda Pharmaceuticals (VNDA) Assets Average (2011 - 2026)
Vanda Pharmaceuticals (VNDA) posted Assets Average of $461.2 million for Q1 2026, down 15.38% sequentially from $545.0 million in Q4 2025, and down 28.39% YoY from $644.1 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Assets Average (2011 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $461.2 million in Q1 2026.
- Quarterly Assets Average fell 28.39% year-over-year to $461.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $461.2 million (down 28.39% YoY) and the FY2025 annual result came in at $572.6 million, down 12.22% from the prior year.
- Assets Average retreated to $461.2 million in Q1 2026 per VNDA's latest filing, from $545.0 million in the prior quarter.
- Over five years, Assets Average peaked at $652.0 million in Q2 2024 and troughed at $461.2 million in Q1 2026.
- A 5-year average of $618.3 million and a median of $639.4 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2026: Assets Average rose 11.21% in 2022, then slipped 28.39% in 2026.
- Over 5 years, Assets Average stood at $628.0 million in 2022, then gained by 2.71% to $645.0 million in 2023, then gained by 0.87% to $650.7 million in 2024, then declined by 16.23% to $545.0 million in 2025, then decreased by 15.38% to $461.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $461.2 million, $545.0 million, and $612.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 423.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 423.00 Mn |
| Mar 31, 2026 | 461.24 Mn |
| Dec 31, 2025 | 545.04 Mn |
| Sep 30, 2025 | 612.94 Mn |
| Jun 30, 2025 | 628.34 Mn |
| Mar 31, 2025 | 644.07 Mn |
| Dec 31, 2024 | 650.66 Mn |
| Sep 30, 2024 | 648.24 Mn |
| Jun 30, 2024 | 652.03 Mn |
| Mar 31, 2024 | 650.56 Mn |
| Dec 31, 2023 | 645.02 Mn |
| Sep 30, 2023 | 641.64 Mn |
| Jun 30, 2023 | 643.11 Mn |
| Mar 31, 2023 | 639.39 Mn |
| Dec 31, 2022 | 628.02 Mn |
| Sep 30, 2022 | 615.45 Mn |
| Jun 30, 2022 | 606.33 Mn |
| Mar 31, 2022 | 598.68 Mn |
| Dec 31, 2021 | 586.78 Mn |
| Sep 30, 2021 | 573.71 Mn |